Compare NTLA & WMK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTLA | WMK |
|---|---|---|
| Founded | 2014 | 1912 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Food Chains |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2016 | 1994 |
| Metric | NTLA | WMK |
|---|---|---|
| Price | $10.89 | $76.53 |
| Analyst Decision | Buy | |
| Analyst Count | 23 | 0 |
| Target Price | ★ $20.02 | N/A |
| AVG Volume (30 Days) | ★ 4.3M | 138.2K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 1.96% |
| EPS Growth | ★ 27.43 | N/A |
| EPS | N/A | ★ 1.13 |
| Revenue | $67,671,000.00 | ★ $4,714,573,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $62.75 | N/A |
| P/E Ratio | ★ N/A | $66.13 |
| Revenue Growth | ★ 16.92 | 0.01 |
| 52 Week Low | $7.95 | $59.99 |
| 52 Week High | $28.24 | $83.74 |
| Indicator | NTLA | WMK |
|---|---|---|
| Relative Strength Index (RSI) | 32.00 | 47.78 |
| Support Level | $8.59 | $76.47 |
| Resistance Level | $15.52 | $82.50 |
| Average True Range (ATR) | 0.80 | 2.16 |
| MACD | -0.35 | -0.53 |
| Stochastic Oscillator | 10.20 | 43.09 |
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Weis Markets Inc is a U.S.-based company that is principally engaged in retailing food products in Pennsylvania and surrounding states. The company's products mainly belong to the following categories: center-store goods, fresh goods, pharmacy services, fuel, and others. The center-store goods include groceries, dairy products, frozen foods, alcoholic beverages, and general merchandise items. The fresh goods include meats, seafood, floral, prepared foods, and bakery products. The center-store goods and fresh goods jointly account for the majority of the company's total revenue.